Back to Browse Journals » Virus Adaptation and Treatment » Volume 3

A paradigm linking herpesvirus immediate-early gene expression apoptosis and myalgic encephalomyelitis chronic fatigue syndrome

Authors A Martin Lerner, Safedin Beqaj

Published Date February 2011 Volume 2011:3 Pages 19—24

DOI http://dx.doi.org/10.2147/VAAT.S15105

Published 21 February 2011

A Martin Lerner1, Safedin Beqaj2
1Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; 2DCL Medical Laboratories, Indianapolis, IN, USA

Abstract: There is no accepted science to relate herpesviruses (Epstein–Barr virus [EBV], human cytomegalovirus [HCMV], and human herpesvirus 6 [HHV6]) as causes of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). ME/CFS patients have elevated serum immunoglobulin (Ig)G serum antibody titers to EBV, HCMV, and HHV6, but there is no herpesvirus DNA-emia, herpesvirus antigenemia, or uniformly elevated IgM serum antibody titers to the complete virions. We propose that herpesvirus EBV, HCMV, and HHV6 immediate-early gene expression in ME/CFS patients leads to host cell dysregulation and host cell apoptosis without lytic herpesvirus replication. Specific antiviral nucleosides, which alleviate ME/CFS, namely valacyclovir for EBV ME/CFS and valganciclovir for HCMV/HHV6 ME/CFS, inhibit herpesvirus DNA polymerases and/or thymidine kinase functions, thus inhibiting lytic virus replication. New host cell recruitment thus ceases. In the absence of new herpesvirus, nonpermissive herpesvirus replication stops, and ME/CFS recovery ensues.

Keywords: ME/CFS, Epstein–Barr virus (EBV), human cytomegalovirus (HCMV), HHV6, abortive replication

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Visual fields in a chloroquine treatment

García-Domene MC, Díez-Ajenjo MA, de Fez MD, Luque MJ

Clinical Optometry 2014, 6:59-70

Published Date: 30 September 2014

Visual performance and aberration associated with contact lens wear in patients with keratoconus: a pilot study

Abdu M, Mohidin N, Mohd-Ali B

Clinical Optometry 2014, 6:47-57

Published Date: 16 August 2014

Differences in daily disposable circle lens performance characteristics

Schafer JM, Reindel WT, Rah MJ, Chan O, Zhang L

Clinical Optometry 2014, 6:37-42

Published Date: 3 April 2014

Reinventing your primary care practice: becoming an MDCEO™

Conard SE, Courtney MR

Journal of Healthcare Leadership 2013, 5:1-8

Published Date: 7 March 2013

Certolizumab in the long-term treatment of rheumatoid arthritis

Khan A, Scott DL

Open Access Rheumatology: Research and Reviews 2011, 3:63-71

Published Date: 26 August 2011

Mobile eye screenings for Hawaii’s homeless: results and applications

Jason B Barnes, Shawn S Barnes, Christian R Small, et al

Clinical Optometry 2010, 2:73-77

Published Date: 12 August 2010

Psychopharmacology of ADHD in pediatrics: current advances and issues

Donald E Greydanus, Ahsan Nazeer, Dilip R Patel

Neuropsychiatric Disease and Treatment 2009, 5:171-181

Published Date: 5 March 2009